Date: 2013-09-18
Type of information: Private placement
Company: Protalix BioTherapeutics (Israel)
Investors:
Amount: $66.8 million
Funding type: private placement
Planned used: The Company intends to use the net proceeds from this offering to fund clinical trials for its product candidates, to fund its research and development activities, to enhance its manufacturing capacity and for working capital and general corporate purposes.
Others: * On September 18, 2013, Protalix BioTherapeutics has announced the closing of its offering of $69 million principal amount of its 4.50% Convertible Notes due 2018 through a private offering, including $9 million aggregate principal amount of Notes related to the initial purchaser\'s over-allotment option, which was exercised in full. The Notes are the unsecured, unsubordinated obligations of the Company. Interest on the Notes is payable semi-annually at a rate of 4.50% per annum, and the Notes will mature on September 15, 2018, unless earlier repurchased, converted or redeemed.
Net proceeds received by the Company from the offering of the Notes were approximately $66.8 million, after deducting the initial purchaser's discount and estimated offering expenses payable by the Company.
Therapeutic area: Rare diseases - Autoimmune diseases - Genetic diseases
